Actinium Pharmaceuticals to present Actimab-A safety and tolerability data at ASH26

Actinium Pharmaceuticals to present Actimab-A safety and tolerability data at ASH26
Actinium posts Actimab-A data at ASH26

Actinium Pharmaceuticals announced that an abstract on its Actimab-A therapy has been accepted for a poster presentation at ASH26. The research addresses the long-term safety and tolerability of Actimab-A in combination with CLAG-M for patients with relapsed or refractory acute myeloid leukemia (AML).

The poster will provide clinical insights into the use of Actimab-A in combination therapies for difficult-to-treat AML cases.

Actinium Pharmaceuticals has recently presented preclinical data on ATNM-400 in lung, colorectal, and ovarian cancer models at EANM26 in Vienna. The company also delivered updates on ATNM-400 clinical and preclinical research in major cancer indications in a separate oncology research report. These activities reflect an ongoing focus on advancing targeted therapies for cancer.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.